Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Moderna’s bivalent shot boosts antibodies against latest omicron strains in trial

Moderna Inc.’s booster shot of its bivalent vaccine sharply increased antibody levels against recent COVID-19 strains when compared to a fourth dose of its original immunization.

Tribune News Service

Moderna Surges On New Omicron Data, Pulling Pfizer, BioNTech Along For The Ride

Moderna stock popped Monday after the company said its bivalent Covid booster led to a 15-fold jump in omicron-blocking antibodies.

Investors Business Daily

Lordstown Motors, eBay And 2 Other Stocks Insiders Are Selling

The Nasdaq Composite jumped over 750 points on Thursday. Investors, meanwhile, focused on some notable insider trades.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

EU watchdog backs Sanofi Covid booster jab

The Hague (AFP) - The EU on Thursday approved a Covid booster vaccine by French drug maker Sanofi and Britain's GSK after it gave positive results against the Omicron variant in trials.

AFP

Check Out What Whales Are Doing With MRNA

Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Pfizer’s COVID cash powers a ‘marketing machine’ on the hunt for new supernovas

For drugmaker Pfizer, a fortune amassed in the COVID pandemic is now paving the path to pharma nirvana: a weight loss pill worth billions.

Tribune News Service

Biotech Firestorm Takes Down Novavax Despite Quadrupled Sales

Novavax posted an unexpected third-quarter loss, and NVAX stock yo-yoed Wednesday despite better-than-expected sales.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Vulnerable Australians want access to another booster dose. Here's the state of play across the country

As COVID cases rise across the country, there are calls for additional booster doses to be made available to Australians who want it.

ABC News

Pfizer is on the hunt for new blockbuster drugs, backed by its COVID fortune

While sales of its COVID vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

Fortune

This Key Piece Of News Could Spark BioNTech, Moderna — And Stoke Demand For Covid Boosters

Covid vaccine stocks surged Friday after a new study suggested an added benefit of the updated omicron-targeting boosters.

Investors Business Daily

Gold Drops Over 1%; Moderna Reports Downbeat Q3 Results

U.S. stocks traded mostly lower toward the end of trading, with the Nasdaq Composite dropping over 100 points on Thursday.

Benzinga

BioNTech Shares Up On Hope For Combined Flu, Covid Shot

Pfizer and BioNTech started testing a combined flu and Covid vaccine on Thursday, helping BNTX stock pare earlier Moderna-inspired losses.

Investors Business Daily

Stock Market Extends Losses Despite Easing Labor Costs; Qualcomm, Roku At New Lows

The stock market fell Thursday despite weaker-than-expected labor costs. Qualcomm and Roku dragged stocks lower.

Investors Business Daily

Moderna Sinks On Slashed Outlook, But Rivals Recovering From Setback

Moderna stock dropped Thursday after the company slashed its 2022 outlook, noting supply issues have delayed some of its deliveries.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Street

Moderna Stock Tumbles On Softer Covid Vaccine Sales Forecast, Weakening Q3 Profits

Moderna cautioned Thursday that $2 billion to $3 billion of its vaccine sales could be pushed into next year amid broader supply chain challenges.

The Guardian - US

The ProPublica-Vanity Fair report on Covid’s origins is explosive. Is it reliable?

Critics say the article is flawed. But that shouldn’t discredit the lab leak theory

Benzinga

This Is What Whales Are Betting On Moderna

Someone with a lot of money to spend has taken a bearish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

PepsiCo, Walmart And 2 Other Stocks Insiders Are Selling

The Nasdaq Composite gained by over 300 points on Friday. Investors, meanwhile, focused on some notable insider trades.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Moderna Unusual Options Activity

A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 17 strange trades.

The Street

Merck Stock Jumps As Keytruda Sales Power Q3 Earnings Beat, Profit Forecast Boost

"We continue to execute on our strategy, invest in leading-edge science and drive innovation," said CEO Robert Davis.

Investors Business Daily

Pfizer Quadruples Its Covid Shot Price — And Other Vaccine Stocks Rocket

Moderna snagged an upgrade Friday on views it will hike charges for its Covid vaccine, as Pfizer plans to charge up to $130 for its shot.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 21, 2022

Upgrades

Tribune News Service

As links to MS deepen, researchers accelerate efforts to develop an Epstein-Barr vaccine

Maybe you’ve never heard of the Epstein-Barr virus. But it knows all about you.

Investors Business Daily

Moderna Stock Fails At Declining 50-Day Average; Check Out This Bearish Option Play

Traders who think Moderna stock will not reclaim the 50-day line could look at a bear call spread at 145-150.

The Independent UK

Moderna jab ‘to protect through the winter’ after positive new results

The main Covid-19 booster offers good protection for at least three months.

1 … 14 15 16 17

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.